BELLUS Health Inc. (BLU)
| Previous close | 7.16 |
| Open | 7.17 |
| Bid | 7.12 x 900 |
| Ask | 7.14 x 1100 |
| Day's range | 7.05 - 7.30 |
| 52-week range | 6.22 - 12.69 |
| Volume | |
| Avg. volume | 670,791 |
| Market cap | 903.76M |
| Beta (5Y monthly) | -0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.69 |
| Earnings date | 09 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.01 |
- Business Wire
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
LAVAL, Quebec, March 21, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the year ended December 31, 2022.
- Business Wire
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
LAVAL, Quebec, March 01, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held Ma
- Business Wire
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
LAVAL, Quebec, February 08, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) A
